Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
July 31, 2024 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...
Safe Harbor Financial to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
July 31, 2024 08:30 ET
|
Safe Harbor Financial Services, Inc.
Company to host conference call after the market closes at 4:30 p.m. ET on Wednesday, August 14th GOLDEN, Colo., July 31, 2024 (GLOBE NEWSWIRE) -- SHF Holdings, Inc., d/b/a/ Safe Harbor Financial...
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
July 31, 2024 08:30 ET
|
Allogene Therapeutics, Inc.
Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...
Global Mofy CEO Invited by NVIDIA China to Engage with Industry Leaders at SIGGRAPH 2024
July 31, 2024 08:30 ET
|
Global Mofy Metaverse Limited
Global Mofy CEO Haogang Yang participated in SIGGRAPH 2024, exploring NVIDIA's AI advancements and showcasing Gausspeed's integration with NVIDIA technolog
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
July 31, 2024 08:05 ET
|
Athira Pharma, Inc.
Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment,...
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
July 31, 2024 08:02 ET
|
Ardelyx, Inc.
WALTHAM, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.
July 31, 2024 08:01 ET
|
PowerUp Acquisition Corp.
Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of a multi-faceted patent protected disruptive drug delivery mechanism...
Spectral AI Announces Continuing Progress in Development of Handheld DeepView SnapShot M® for Military Field Use
July 31, 2024 08:00 ET
|
Spectral AI, Inc.
DALLAS, July 31, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and...
Olaplex Holdings, Inc. Announces Participation in the Canaccord Genuity 44th Annual Growth Conference on August 14th
July 31, 2024 08:00 ET
|
Olaplex Holdings, Inc.
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (“OLAPLEX”), today announced their participation in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA. Amanda...
Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence
July 31, 2024 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...